182 related articles for article (PubMed ID: 33199365)
1. K
Bukhari M; Deng H; Sipes D; Ruane-Foster M; Purdy K; Woodworth CD; Sur S; Samways DSK
J Biol Chem; 2021; 296():100084. PubMed ID: 33199365
[TBL] [Abstract][Full Text] [Related]
2. Selective permeabilization of cervical cancer cells to an ionic DNA-binding cytotoxin by activation of P2Y receptors.
Bukhari M; Deng H; Jones N; Towne Z; Woodworth CD; Samways DS
FEBS Lett; 2015 Jun; 589(13):1498-504. PubMed ID: 25937122
[TBL] [Abstract][Full Text] [Related]
3. Calcium-gated K
Tarasov MV; Bystrova MF; Kotova PD; Rogachevskaja OA; Sysoeva VY; Kolesnikov SS
Pflugers Arch; 2017 Feb; 469(2):349-362. PubMed ID: 28028617
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of KCa3.1 by depolarisation and 2-aminoethoxydiphenyl borate (2-APB) during Ca²⁺ release activated Ca²⁺ (CRAC) entry in human erythroleukemia (HEL) cells: Implications for the interpretation of 2-APB inhibition of CRAC entry.
Littlechild R; Zaidman N; Khodaverdi D; Mason MJ
Cell Calcium; 2015 Feb; 57(2):76-88. PubMed ID: 25601026
[TBL] [Abstract][Full Text] [Related]
5. Calcium-dependent potassium channels control proliferation of cardiac progenitor cells and bone marrow-derived mesenchymal stem cells.
Vigneault P; Naud P; Qi X; Xiao J; Villeneuve L; Davis DR; Nattel S
J Physiol; 2018 Jun; 596(12):2359-2379. PubMed ID: 29574723
[TBL] [Abstract][Full Text] [Related]
6. Voltage dependence of the Ca(2+)-activated K(+) channel K(Ca)3.1 in human erythroleukemia cells.
Stoneking CJ; Shivakumar O; Thomas DN; Colledge WH; Mason MJ
Am J Physiol Cell Physiol; 2013 May; 304(9):C858-72. PubMed ID: 23407879
[TBL] [Abstract][Full Text] [Related]
7. The combined activation of K
Pillozzi S; D'Amico M; Bartoli G; Gasparoli L; Petroni G; Crociani O; Marzo T; Guerriero A; Messori L; Severi M; Udisti R; Wulff H; Chandy KG; Becchetti A; Arcangeli A
Br J Cancer; 2018 Jan; 118(2):200-212. PubMed ID: 29161243
[TBL] [Abstract][Full Text] [Related]
8. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3.
Oliván-Viguera A; Valero MS; Murillo MD; Wulff H; García-Otín AL; Arbonés-Mainar JM; Köhler R
PLoS One; 2013; 8(3):e58614. PubMed ID: 23516517
[TBL] [Abstract][Full Text] [Related]
9. PKA reduces the rat and human KCa3.1 current, CaM binding, and Ca2+ signaling, which requires Ser332/334 in the CaM-binding C terminus.
Wong R; Schlichter LC
J Neurosci; 2014 Oct; 34(40):13371-83. PubMed ID: 25274816
[TBL] [Abstract][Full Text] [Related]
10. K
Bonito B; Sauter DR; Schwab A; Djamgoz MB; Novak I
Pflugers Arch; 2016 Nov; 468(11-12):1865-1875. PubMed ID: 27752766
[TBL] [Abstract][Full Text] [Related]
11. K
Robles-Martínez L; Garay E; Martel-Gallegos MG; Cisneros-Mejorado A; Pérez-Montiel D; Lara A; Arellano RO
Sci Rep; 2017 Jun; 7(1):4340. PubMed ID: 28659615
[TBL] [Abstract][Full Text] [Related]
12. The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling.
Bi D; Toyama K; Lemaître V; Takai J; Fan F; Jenkins DP; Wulff H; Gutterman DD; Park F; Miura H
J Biol Chem; 2013 May; 288(22):15843-53. PubMed ID: 23609438
[TBL] [Abstract][Full Text] [Related]
13. Orai/CRACM1 and KCa3.1 ion channels interact in the human lung mast cell plasma membrane.
Duffy SM; Ashmole I; Smallwood DT; Leyland ML; Bradding P
Cell Commun Signal; 2015 Jul; 13():32. PubMed ID: 26177720
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-conductance calcium-activated potassium channel KCa3.1 and chloride channel modulate chemokine ligand (CCL19/CCL21)-induced migration of dendritic cells.
Shao Z; Gaurav R; Agrawal DK
Transl Res; 2015 Jul; 166(1):89-102. PubMed ID: 25583444
[TBL] [Abstract][Full Text] [Related]
15. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Sankaranarayanan A; Raman G; Busch C; Schultz T; Zimin PI; Hoyer J; Köhler R; Wulff H
Mol Pharmacol; 2009 Feb; 75(2):281-95. PubMed ID: 18955585
[TBL] [Abstract][Full Text] [Related]
16. Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators.
Jenkins DP; Yu W; Brown BM; Løjkner LD; Wulff H
Assay Drug Dev Technol; 2013; 11(9-10):551-60. PubMed ID: 24351043
[TBL] [Abstract][Full Text] [Related]
17. Investigating CFTR and KCa3.1 Protein/Protein Interactions.
Klein H; Abu-Arish A; Trinh NT; Luo Y; Wiseman PW; Hanrahan JW; Brochiero E; Sauvé R
PLoS One; 2016; 11(4):e0153665. PubMed ID: 27092946
[TBL] [Abstract][Full Text] [Related]
18. Role of KCa3.1 Channels in Modulating Ca
Catacuzzeno L; Franciolini F
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274242
[TBL] [Abstract][Full Text] [Related]
19. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca2+ -activated K+ -channels.
Hasenau AL; Nielsen G; Morisseau C; Hammock BD; Wulff H; Köhler R
Acta Physiol (Oxf); 2011 Sep; 203(1):117-26. PubMed ID: 21362152
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the Ca
Kito H; Morihiro H; Sakakibara Y; Endo K; Kajikuri J; Suzuki T; Ohya S
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C345-C358. PubMed ID: 32520608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
